References
- Blum R H, Carter S K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249–259
- Lefrak E A, Pitha J, Rosenheim S, Gottlieb J A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973; 32: 302–314
- Lipshultz S E, Colan S D, Gelber R D, Perez-Atayde A R, Sallan S E, Sanders S P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–815
- Lipshultz S E, Lipsitz S, Goorin A M, Sallan S E, Mone S M, Sanders S P, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738–1743
- Legha S S, Benjamin R S, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139
- Berrak S G, Ewer M S, Jaffe N, Pearson P, Ried H, Zietz H A, et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8: 611–614
- Ishisaka T, Kishi S, Okura K, Horikoshi M, Yamashita T, Mitsuke Y, et al. A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin. Leuk Lymphoma 2006; 47: 1599–1607
- Lipshultz S E, Giantris A L, Lipsitz S R, Dalton V K, Asselin B L, Barr R D, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20: 1677–1682
- Silverman L B, Gelber R D, Dalton V K, Asselin B L, Barr R D, Clavell L A, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218
- Levitt G A, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Haematol 2004; 124: 463–468
- Ewer M S, Jaffe N, Ried H, Zietz H A, Benjamin R S. Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 1998; 31: 512–515
- Lipshultz S E, Lipsitz S R, Sallan S E, Dalton V M, Mone S M, Gelber R D, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629–2636
- Lipshultz S E, Rifai N, Dalton V M, Levy D E, Silverman L B, Lipsitz S R, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145–153
- Herman E H, Zhang J, Chadwick D P, Ferrans V J. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000; 45: 329–334
- Caulfield J B, Billner V. Cardiac matrix alterations induced by Adriamycin. Am J Pathol 1988; 133: 298–305
- Lipshultz S, Shanfeld J, Chacko S. Emergence of ß-adrenergic sensitivity in the developing chicken heart. Proc Natl Acad Sci USA 1981; 78: 288–292
- Wildenthal K. Maturation of responsiveness to cardioactive drugs. Differential effects of acetylcholine, norepinephrine, theophylline, tyramine, glucagon, and dibutyryl cyclic AMP on atrial rate in hearts of fetal mice. J Clin Invest 1973; 52: 2250–2258